| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MYL7 |
| Uniprot No | Q01449 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-175aa |
| 氨基酸序列 | MGSSHHHHHH SSGLVPRGSH MGSHMASRKA GTRGKVAATK QAQRGSSNVF SMFEQAQIQE FKEAFSCIDQ NRDGIICKAD LRETYSQLGK VSVPEEELDA MLQEGKGPIN FTVFLTLFGE KLNGTDPEEA ILSAFRMFDP SGKGVVNKDE FKQLLLTQAD KFSPAEVEQM FALTPMDLAG NIDYKSLCYI ITHGDEKEE |
| 预测分子量 | 22 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MYL7重组蛋白的模拟参考文献示例(实际文献需通过学术数据库验证)：
---
1. **标题**：*Recombinant Expression and Functional Characterization of Human MYL7 in Cardiomyocytes*
**作者**：Chen, L. et al.
**摘要**：研究报道了人源MYL7蛋白在大肠杆菌中的重组表达及纯化，并验证其在心肌细胞收缩功能中的作用。实验表明，重组MYL7可恢复心肌细胞中肌球蛋白轻链缺陷导致的收缩异常。
2. **标题**：*Structural Insights into MYL7 Mutations Linked to Congenital Heart Disease*
**作者**：Wang, Y. et al.
**摘要**：通过重组MYL7蛋白的晶体结构解析，揭示了与先天性心脏病相关的突变位点(如R58C)如何破坏其与肌球蛋白重链的相互作用，为病理机制提供分子基础。
3. **标题**：*Development of a MYL7-Specific ELISA Using Recombinant Protein for Clinical Diagnostics*
**作者**：Kim, S. et al.
**摘要**：利用昆虫细胞系统表达重组MYL7蛋白，开发了一种高灵敏度的ELISA检测方法，用于心肌病患者的血液标志物筛查，验证了其在临床中的潜在应用价值。
4. **标题**：*Functional Analysis of MYL7 Phosphorylation Sites via Recombinant Mutagenesis*
**作者**：Garcia, R. et al.
**摘要**：通过位点特异性突变重组MYL7蛋白，研究丝氨酸/苏氨酸磷酸化修饰对其调控心肌收缩力的影响，发现S15位点的磷酸化是功能关键。
---
**注**：以上为基于MYL7常见研究方向的假设性示例，实际文献需通过PubMed、Web of Science等平台检索关键词(如“MYL7 recombinant”“MYL7 expression”)获取。
**Background of MYL7 Recombinant Protein**
MYL7. or Myosin Light Chain 7. is a regulatory component of the myosin motor complex, primarily expressed in cardiac and skeletal muscle tissues. It belongs to the myosin light chain family, which modulates the ATPase activity of myosin heavy chains (e.g., MYH6/MYH7), thereby influencing muscle contraction. MYL7 specifically associates with the atrial-specific myosin heavy chain, playing a critical role in cardiac development and function. Mutations or dysregulation of MYL7 have been linked to congenital heart defects, cardiomyopathies, and arrhythmias, highlighting its importance in maintaining cardiac homeostasis.
Recombinant MYL7 protein is engineered using heterologous expression systems (e.g., *E. coli* or mammalian cells*) to produce purified, functional protein for research and therapeutic applications. Its production often involves tagging (e.g., His-tag) to facilitate purification and detection. Recombinant MYL7 retains the ability to bind myosin heavy chains and calcium ions, enabling studies on its structural and functional interactions within the sarcomere.
In research, MYL7 recombinant protein is utilized to investigate molecular mechanisms underlying heart development, muscle contraction dynamics, and disease pathogenesis. It serves as a tool for *in vitro* assays, such as binding studies, enzymatic activity assays, and cellular models of cardiac dysfunction. Additionally, it supports drug discovery efforts targeting myosin-related disorders.
Recent studies emphasize MYL7's potential as a biomarker for cardiac injury and a therapeutic target for heart failure. Its recombinant form accelerates translational research, bridging gaps between basic science and clinical applications in cardiovascular medicine. Continued exploration of MYL7 interactions and signaling pathways may unveil novel strategies for treating muscle-related diseases.
(Word count: 249)
×
